Podcast

Europe has finalised its agreement with Sanofi and GSK for 300 million doses of their vaccine candidate while two companies have published the detailed clinical trial protocols for their candidates.

Medicines Australia says less access to new medicines through the PBS is the 'only likely outcome' of the 'most favoured nation' pricing mandate proposed by US President Donald Trump. President...

The federal government now wants certainty on any PBS savings it negotiates with the industry with the option to introduce a new statutory price reduction to 'insure' against the non-appearance of second brands.

Cerecin is an emerging company with a portfolio focused on developing new treatments for the central nervous system, including migraine, and it recently established its Australian corporate presence.

The federal government has announced funding from the MRFF for three more Australian COVID-19 vaccine candidates, including one based on mRNA technology and another administered using a needle-free system.

NPS MedicineWise effectively sold access to data collected from thousands of GP clinics under a government-funded initiative through its now closed commercial arm VentureWise.

A new report has revealed the hidden burden of non-melanoma skin cancer that is causing an estimated four deaths per day in Australia and hardship for those who live with the disease. The...

Medicines Australia's PharmAus is over for another year with a final session including an address from health minister Greg Hunt and a discussion on the economy, vaccines and the future funding of health.

Members of the National Pharmaceutical Services Association say they welcome the ACCC's decision to authorise continued cooperation on the distribution of medicines during the COVID-19 pandemic.

Sanofi Australia and New Zealand has been recognised with Platinum awards for 'Best Wellbeing Team' and 'Best Wellbeing Strategy' at yesterday's 2020 LearnX Live.

The review of NPS MedicineWise led by former PBAC chair Emeritus Professor Lloyd Sansom AO found it was likely using its grant from the Department of Health to fund its commercial activities.

The review of NPS MedicineWise led by former PBAC chair Emeritus Professor Lloyd Sansom AO delivered a scathing assessment of aspects of its operation, including a lack of transparency and the use of commonwealth funds to support its commercial activities.